ArticleJTCVS structural and endovascular2026
Surgical management of infected thoracic endografts: A single-center experience.
Article in JTCVS structural and endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Thoracic endovascular aortic repair is the preferred approach for treating pathology of the descending thoracic aorta. Infection after thoracic endovascular aortic repair is reported to occur in less than 1% of patients and is associated with significant mortality. The purpose of the present study is to describe the surgical management and outcomes of patients who underwent explant of infected thoracic endovascular aortic repairs at our institution. Methods: Patients with an infected thoracic endovascular aortic repair who underwent surgical management at our institution between January 2017 and June 2024 were included. Chart review was performed to identify comorbidities and operative variables including method of reconstruction, postoperative complications, and mortality. Results: Nine patients were identified in the study period. There were 7 men and 2 women with an age range of 29 to 67 years. Indications for thoracic endovascular aortic repair included type B aortic dissection, pseudoaneurysm, and rupture of the descending thoracic aorta. The median time from endograft implant to diagnosis of infection was 182 days (range, 31-1826 days). The causative infectious organism was identified in 77% of cases (7/9). Five patients underwent extra-anatomic bypass and aortic ligation followed by interval thoracic endovascular aortic repair explant. Four patients underwent thoracic endovascular aortic repair explant and in situ aortic reconstruction. There were no instances of graft thrombosis. In-hospital mortality was 22% (2 patients) with 1-year mortality of 50% (4 patients). One patient was lost to follow-up. Conclusions: As thoracic endovascular aortic repair volume continues to increase, the prevalence of thoracic endograft infection will continue to increase. Our experience demonstrates thoracic aortic endograft explantation with extra-anatomic or in-line aortic reconstruction is viable; however, mortality from this pathology and its management remain high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.